[go: up one dir, main page]

MA29612B1 - Composes et methodes de modulation de la kinase et instructions afferentes - Google Patents

Composes et methodes de modulation de la kinase et instructions afferentes

Info

Publication number
MA29612B1
MA29612B1 MA30548A MA30548A MA29612B1 MA 29612 B1 MA29612 B1 MA 29612B1 MA 30548 A MA30548 A MA 30548A MA 30548 A MA30548 A MA 30548A MA 29612 B1 MA29612 B1 MA 29612B1
Authority
MA
Morocco
Prior art keywords
compounds
methods
related instructions
modulating kinase
raf
Prior art date
Application number
MA30548A
Other languages
English (en)
Inventor
Prahbha N Ibrahim
Dean R Artis
Ryan Bremer
Shumeye Mamo
Marika Nespi
Chao Zhang
Jiazhong Zhang
Yong-Liang Zhu
James Tsai
Klaus-Peter Hirth
Gideon Bollag
Wayne Spevak
Hanna Cho
Samuel J Gillette
Guoxiam Wu
Hongyao Zhu
Shenghua Shi
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37033831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29612(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of MA29612B1 publication Critical patent/MA29612B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/62—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
    • C07C39/27—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being bound to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Composés actifs sur les protéines kinases, ainsi que méthodes d'utilisation de ces composés pour le traitement de pathologies et de symptômes associés à une activité aberrante des protéines kinases, y compris les kinases B-Raf, c-Raf-1, Fms, Jnk1, Jnk2, Jnk3 et Kit, ainsi que toutes mutations de celles-ci.
MA30548A 2005-06-22 2008-01-07 Composes et methodes de modulation de la kinase et instructions afferentes MA29612B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69296005P 2005-06-22 2005-06-22
US73152805P 2005-10-28 2005-10-28

Publications (1)

Publication Number Publication Date
MA29612B1 true MA29612B1 (fr) 2008-07-01

Family

ID=37033831

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30548A MA29612B1 (fr) 2005-06-22 2008-01-07 Composes et methodes de modulation de la kinase et instructions afferentes

Country Status (35)

Country Link
US (10) US7863288B2 (fr)
EP (3) EP3088400A1 (fr)
JP (1) JP5007304B2 (fr)
KR (1) KR101125919B1 (fr)
CN (3) CN101243084B (fr)
AR (2) AR054624A1 (fr)
AT (1) ATE518860T1 (fr)
AU (1) AU2006261993B2 (fr)
BE (1) BE2012C028I2 (fr)
BR (1) BRPI0611863B1 (fr)
CA (1) CA2613015C (fr)
CR (2) CR9677A (fr)
CY (2) CY1111996T1 (fr)
DE (1) DE122012000043I1 (fr)
DK (2) DK1893612T3 (fr)
EC (1) ECSP088121A (fr)
ES (2) ES2565992T3 (fr)
HU (2) HUE027370T2 (fr)
IL (1) IL188248A (fr)
LU (1) LU92035I2 (fr)
MA (1) MA29612B1 (fr)
MX (1) MX2007016463A (fr)
MY (2) MY153898A (fr)
NO (2) NO333913B1 (fr)
NZ (1) NZ565255A (fr)
PE (1) PE20070100A1 (fr)
PL (2) PL2395004T3 (fr)
PT (1) PT1893612E (fr)
RS (1) RS52010B (fr)
RU (3) RU2565071C2 (fr)
SI (2) SI1893612T1 (fr)
TW (3) TWI522337B (fr)
UA (1) UA95244C2 (fr)
WO (2) WO2007002325A1 (fr)
ZA (4) ZA200711152B (fr)

Families Citing this family (441)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1696920T1 (sl) 2003-12-19 2015-02-27 Plexxikon Inc. Spojine in postopki za razvoj modulatorjev ret
KR101216372B1 (ko) 2004-03-30 2013-01-04 버텍스 파마슈티칼스 인코포레이티드 Ｊａｋ 및 기타 단백질 키나제의 억제제로서 유용한 아자인돌
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
EP1797881B1 (fr) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Composition medicamenteuse avec une stabilite amelioree et une tendence de gelification reduite
WO2007013896A2 (fr) 2005-05-17 2007-02-01 Plexxikon, Inc. Composes modulant l'activite de c-kit et c-fms et utilisations
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EP1910358A2 (fr) 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocycles inhibiteurs de janus kinase-3
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
AU2006285673B2 (en) * 2005-09-01 2010-12-02 Eisai R&D Management Co., Ltd. Method for preparation of pharmaceutical composition having improved disintegratability
EP3838903B1 (fr) 2005-12-13 2023-11-22 Incyte Holdings Corporation Dérivé du pyrrolo[2,3-b]pyrimidine en tant qu'inhibiteur de la janus kinase
CN104650077A (zh) 2006-01-17 2015-05-27 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
TW200738709A (en) * 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
JP5099005B2 (ja) * 2006-04-03 2012-12-12 アステラス製薬株式会社 ヘテロ化合物
CA2652442C (fr) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Agent antitumoral destine au cancer de la thyroide
EP2029593A1 (fr) * 2006-05-22 2009-03-04 AstraZeneca AB Dérivés de l'indole
US7964728B2 (en) 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
JP2009542596A (ja) * 2006-07-06 2009-12-03 ソルベイ・フアーマシユーチカルズ・ベー・ブイ 部分的ニコチン性アセチルコリン受容体活性化作用およびドパミン再取り込み阻害の組合せをもつアザインドール誘導体
GB0617161D0 (en) * 2006-08-31 2006-10-11 Vernalis R&D Ltd Enzyme inhibitors
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
WO2008063888A2 (fr) * 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
WO2008079909A1 (fr) * 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
JP5406039B2 (ja) 2006-12-21 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
BRPI0720695A2 (pt) * 2006-12-21 2014-02-18 Plexxikon Inc Compostos e métodos para modulação de cinase, e indicações para estes
SG10201508035TA (en) * 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
AU2008239594B2 (en) 2007-04-13 2013-10-24 Beth Israel Deaconess Medical Center Methods for treating cancer resistant to ErbB therapeutics
GB0710528D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
CN101932582B (zh) 2007-06-13 2013-09-25 因塞特公司 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐
MX2010000617A (es) * 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
MX2010001636A (es) * 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
WO2009026239A1 (fr) * 2007-08-17 2009-02-26 University Of Maryland, Baltimore Inhibiteurs à petites molécules de la liaison au domaine lck sh2
CA2639416C (fr) 2007-09-11 2019-12-31 F. Hoffmann-La Roche Ag Test de diagnostic pour la susceptibilite aux inhibiteurs de la b-raf kinase
DE102007045919B4 (de) 2007-09-26 2018-07-05 Bayer Intellectual Property Gmbh Wirkstoffkombinationen mit insektiziden und akariziden Eigenschaften
DE102007045956A1 (de) 2007-09-26 2009-04-09 Bayer Cropscience Ag Wirkstoffkombination mit insektiziden und akariziden Eigenschaften
JP2011500806A (ja) 2007-10-25 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
JP5608097B2 (ja) 2008-01-08 2014-10-15 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害薬としてのピロロピリジン
US8426396B2 (en) * 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
CN101965347B (zh) 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
US20110282056A1 (en) * 2008-01-22 2011-11-17 Merck Patent Gmbh Protein kinase inhibitors and use thereof
WO2009106445A1 (fr) * 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Inhibiteurs de kinase pyrrolopyrazine
CN102149712A (zh) 2008-02-29 2011-08-10 阵列生物制药公司 吡唑并[3，4-b]吡啶Raf抑制剂
CN102015707A (zh) 2008-02-29 2011-04-13 阵列生物制药公司 Raf抑制剂化合物及其使用方法
WO2009111280A1 (fr) 2008-02-29 2009-09-11 Array Biopharma Inc. Dérivés de n-(6-aminopyridin-3-yl)-3-(sulfonamido) benzamide comme inhibiteurs de b-raf pour le traitement du cancer
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
WO2009143018A2 (fr) 2008-05-19 2009-11-26 Plexxikon, Inc. Composés et procédés de modulation des kinases, et indications associées
JP2011520937A (ja) * 2008-05-21 2011-07-21 ビーエーエスエフ ソシエタス・ヨーロピア 殺菌剤としての置換ピリジン−４−イルメチルスルホンアミド
JP2011521924A (ja) * 2008-05-28 2011-07-28 ビーエーエスエフ ソシエタス・ヨーロピア 殺菌剤としての置換ピリジン−４−イル−メチルスルホンアミド
JP5767965B2 (ja) * 2008-06-10 2015-08-26 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
AR072008A1 (es) * 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
EP2298731A4 (fr) 2008-06-25 2011-09-21 Takeda Pharmaceutical Composé amide
JP5369183B2 (ja) 2008-07-16 2013-12-18 ファーマサイクリックス，インク． 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
DE102008052943A1 (de) 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
JP2012509342A (ja) * 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
AU2009324894B2 (en) * 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
US8318446B2 (en) * 2008-12-05 2012-11-27 California Institute Of Technology DNA-damage-induced proteolysis
CN105418598B (zh) * 2009-02-10 2019-05-17 孟山都技术有限公司 用于控制线虫的组合物和方法
KR20110130463A (ko) 2009-03-11 2011-12-05 플렉시콘, 인코퍼레이티드 Ｒａｆ 키나제의 억제를 위한 피롤로［２,３-ｂ］피리딘 유도체
AR075812A1 (es) * 2009-03-11 2011-04-27 Plexxikon Inc Derivados de pirrol[2,3-b]piridina como inhibidores de raf quinasa
WO2010111527A1 (fr) * 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines en tant qu'inhibiteurs de la kinase et leur utilisation médicale
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
RS59632B1 (sr) 2009-05-22 2020-01-31 Incyte Holdings Corp 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori
US8716303B2 (en) 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101920202B1 (ko) 2009-05-26 2018-11-21 애브비 아일랜드 언리미티드 컴퍼니 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR102050712B1 (ko) 2009-06-17 2019-12-02 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8329724B2 (en) * 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
CA2771403C (fr) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Composition pharmaceutique contenant un derive de quinoleine
IN2012DN01983A (fr) 2009-08-24 2015-07-24 Ascepion Pharmaceuticals Inc
US20120214811A1 (en) 2009-08-28 2012-08-23 Ignacio Aliagas Raf inhibitor compounds and methods of use thereof
EP2470541A1 (fr) 2009-08-28 2012-07-04 Array Biopharma, Inc. Composés inhibiteurs de raf et procédés d'utilisation de ceux-ci
EP2470532A1 (fr) 2009-08-28 2012-07-04 Array Biopharma, Inc. Composés 1h-pyrazolo[3,4-b]pyridines pour l'inhibition des raf kinases
JP2013503190A (ja) 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
EP2470538A1 (fr) * 2009-08-28 2012-07-04 Array Biopharma, Inc. Composés inhibiteurs de raf et leurs procédés d'utilisation
CN102858754A (zh) 2009-08-28 2013-01-02 阵列生物制药公司 Raf抑制剂化合物及其使用方法
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011050344A2 (fr) 2009-10-23 2011-04-28 Mannkind Corporation Immunothérapie pour le cancer et procédé de traitement du cancer
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2011060216A1 (fr) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Azaindoles substitués
PE20121335A1 (es) 2009-11-18 2012-10-12 Plexxikon Inc Compuestos derivados de amida como inhibidores de raf cinasas
DE102009058280A1 (de) * 2009-12-14 2011-06-16 Merck Patent Gmbh Thiazolderivate
RU2012131373A (ru) * 2009-12-23 2014-01-27 Плексксикон, Инк. Соединения и способы модулирования киназы, а также показания для такого модулирования
EP2937345B1 (fr) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase raf de type ii
SG182343A1 (en) 2010-01-06 2012-08-30 Joseph P Errico Methods and compositions of targeted drug development
US8658170B2 (en) 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
AU2011215638B2 (en) * 2010-02-11 2016-04-28 Vanderbilt University Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mGluR4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
ME02386B (fr) 2010-03-10 2016-09-20 Incyte Holdings Corp Dérivés de pipéridin-4-yl azétidine en tant qu'inhibiteurs de jak1
JP2013529181A (ja) 2010-03-25 2013-07-18 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 神経障害を治療するための組成物および方法
PH12012502079A1 (en) 2010-04-16 2013-02-11 Ac Immune Sa Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
WO2011140164A1 (fr) * 2010-05-06 2011-11-10 Merck Sharp & Dohme Corp. Dérivés d'azaindole utilisables en tant que modulateurs de la faah
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP2569315A1 (fr) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
MX2012013467A (es) 2010-05-20 2013-04-29 Array Biopharma Inc Compuestos macrociclicos como inhibidores de trk cinasa.
NZ603686A (en) 2010-05-21 2014-11-28 Incyte Corp Topical formulation for a jak inhibitor
EP2576566B1 (fr) * 2010-05-28 2015-10-28 Merck Sharp & Dohme B.V. Composés thiéno(2,3b)pyrazine en tant qu'inhibiteurs de b-raf
US20120087915A1 (en) 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
WO2011154158A1 (fr) 2010-06-09 2011-12-15 Bayer Bioscience N.V. Procédés et moyens pour modifier un génome végétal au niveau d'une séquence nucléotidique habituellement utilisée dans l'ingénierie des génomes végétaux
US8779150B2 (en) 2010-07-21 2014-07-15 Hoffmann-La Roche Inc. Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
WO2012018639A2 (fr) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions de stabilisation d'adn, d'arn, de protéines salivaires et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120208837A1 (en) 2010-09-13 2012-08-16 Roger Tung Substituted azaindoles
IL225340A (en) 2010-10-29 2017-05-29 Abbvie Inc Solid dispersions containing cell mortality
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
KR101236731B1 (ko) 2010-11-02 2013-02-25 한국과학기술원 아자인돌 화합물, 이를 포함하는 ｐｉ３ｋ 저해제용 약학 조성물 및 ｐｉ３ｋ와 연관된 질환 치료용 약학 조성물
TW201249845A (en) 2010-11-19 2012-12-16 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
SI2643322T1 (en) 2010-11-23 2018-01-31 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US20120129853A1 (en) 2010-11-23 2012-05-24 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
EP2646054A4 (fr) 2010-12-02 2015-03-04 Univ Pittsburgh Méthodes de traitement d'une tumeur au moyen d'un anticorps qui se lie spécifiquement à grp94
US9295669B2 (en) * 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
WO2012083117A1 (fr) 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibiteurs de la réplication des virus de la grippe
CA2824028A1 (fr) 2011-01-06 2012-07-12 Beta Pharma Canada Inc. Nouvelles urees pour le traitement et la prevention du cancer
SI2672967T1 (sl) * 2011-02-07 2018-12-31 Plexxikon Inc. Spojine in postopki za kinazno modulacijo in indikacije zanjo
EP2672963A4 (fr) 2011-02-08 2015-06-24 Childrens Medical Center Méthodes de traitement d'un mélanome
MX357939B (es) 2011-02-18 2018-07-31 Novartis Pharma Ag Terapia de combinacion de inhibidor de objetivo de rapamicina en mamifero/janus cinasa (mtor/jak).
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
EP2686008A1 (fr) * 2011-03-15 2014-01-22 INSERM - Institut National de la Santé et de la Recherche Médicale Compositions et procédés pour l'inhibition du développement d'une tumeur provoquée par une sénescence induite par une chimiothérapie
EP2694072B2 (fr) * 2011-04-01 2024-08-07 Genentech, Inc. Combinaison de composé inhibiteur d'akt et d'abiraterone pour utilisation dans des traitements thérapeutiques
WO2012138809A1 (fr) * 2011-04-05 2012-10-11 Dawei Zhang Utilisation de composés hétérocycliques en tant qu'inhibiteurs des kinases
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
US9222137B2 (en) * 2011-05-10 2015-12-29 Trovagene, Inc. Method for monitoring minimal residual hairy cell leukemia
EP2710003A1 (fr) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
HK1199713A1 (en) 2011-05-17 2015-08-14 普莱希科公司 Kinase modulation and indications therefor
EP2714688B1 (fr) 2011-05-26 2016-02-24 Daiichi Sankyo Company, Limited Composés hétérocycliques comme inhibiteurs de proteines kinases
EP2714937B1 (fr) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
US8877742B2 (en) 2011-06-10 2014-11-04 Glaxosmithkline Intellectual Property Limited Compounds
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
CA2841080A1 (fr) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibiteurs de tyrosine kinase de bruton
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
CA2844507A1 (fr) 2011-08-10 2013-02-14 Novartis Pharma Ag Polytherapie par jak pi3k/mtor
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
WO2013029043A1 (fr) * 2011-08-25 2013-02-28 Reaction Biology Corp. Inhibiteurs sélectifs de kinase
WO2013032951A1 (fr) 2011-08-26 2013-03-07 Neupharma, Inc. Entités chimiques, compositions et procédés
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EP2755657B1 (fr) 2011-09-14 2017-11-29 Neupharma, Inc. Entités chimiques, compositions et procédés
EP2570127A1 (fr) 2011-09-16 2013-03-20 Sanofi Compositions et procédés pour traiter le cancer avec un inhibiteur bêta PI3KB et un inhibiteur de la voie MAPK, incluant des inhibiteurs MEK et RAF
WO2013043715A1 (fr) 2011-09-19 2013-03-28 Genentech, Inc. Polythérapies comportant des antagonistes de c-met et de b-raf
WO2013062945A1 (fr) * 2011-10-24 2013-05-02 Glaxosmithkline Intellectual Property Development Limited Composés chimiques
EP3569598A1 (fr) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibiteurs de la kinase c-jun-n-terminale (jnk)
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
SI2797888T1 (sl) 2011-12-31 2017-01-31 BeiGene, Ltd. Mourant Ozannes Corporate Services (Cayman) Limited Zlite triciklične spojine kot inhibitorji kinaze raf
WO2013109142A1 (fr) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
CN102603734A (zh) * 2012-01-19 2012-07-25 盛世泰科生物医药技术(苏州)有限公司 一种蛋白激酶抑制剂及其应用
WO2013112950A2 (fr) 2012-01-25 2013-08-01 Neupharma, Inc. Entités chimiques particulières, compositions et procédés
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
EP2830608B8 (fr) * 2012-03-28 2020-01-15 UCB Biopharma SRL Dérivés de phénylurée et de phénylcarbamate comme inhibiteurs d'agrégation de protéine
CA2871436C (fr) * 2012-04-23 2020-07-28 Genentech, Inc. Intermediaires et procedes de preparation de composes a utiliser comme inhibiteurs chk1
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP2858501A4 (fr) * 2012-05-22 2015-12-09 Merck Sharp & Dohme Inhibiteurs de kinase trk-a, compositions et méthodes correspondantes
US10077474B2 (en) * 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
BR112014029404A2 (pt) 2012-05-31 2017-06-27 Hoffmann La Roche compostos , composição farmacêutica, utilização de um composto, método para o tratamento ou profilaxia do cancêr e invenção
US9150570B2 (en) * 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
MX348290B (es) 2012-06-04 2017-06-05 Pharmacyclics Llc Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
US9221815B2 (en) 2012-07-03 2015-12-29 Ratiopharm Gmbh Solid state form of vemurafenib choline salt
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
SG11201500883YA (en) * 2012-08-07 2015-04-29 Aurigene Discovery Tech Ltd 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
KR20150038068A (ko) 2012-08-17 2015-04-08 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
CN103626765B (zh) * 2012-08-27 2016-08-10 广东东阳光药业有限公司 取代的氮杂吲哚化合物及其盐、组合物和用途
TWI601725B (zh) * 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
MX2015002887A (es) 2012-09-06 2015-07-06 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
WO2014047648A1 (fr) 2012-09-24 2014-03-27 Neupharma, Inc. Entités chimiques particulières, compositions et procédés
CN103613591B (zh) * 2012-09-29 2016-04-13 上海科州药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
EP2912036A1 (fr) 2012-10-04 2015-09-02 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[3,2-c]pyridine
KR102174576B1 (ko) * 2012-10-08 2020-11-06 아트리바 테라퓨틱스 게엠베하 바이러스 질환 치료에서의 ｍｅｋ 억제제
EP2909194A1 (fr) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
WO2014063054A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
MA38183A1 (fr) 2012-11-15 2017-03-31 Pharmacyclics Inc Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
WO2014100755A2 (fr) 2012-12-20 2014-06-26 Biomatrica, Inc. Formulations et procédés pour stabiliser des réactifs pcr
RU2015115397A (ru) 2012-12-21 2017-01-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аморфная форма производного хинолина и способ его получения
WO2014100620A2 (fr) 2012-12-21 2014-06-26 Plexxikon Inc. Composés et procédés pour la modulation de kinase, et indications associées
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
TW201932456A (zh) 2013-01-15 2019-08-16 美商英塞特控股公司 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
WO2014130856A2 (fr) * 2013-02-21 2014-08-28 Wayne Rothbaum Traitement de troubles associés au squelette
WO2014128235A1 (fr) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Méthodes de traitement du cancer et de prévention de résistance aux médicaments
JP6835472B2 (ja) * 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物
DK2964650T3 (en) 2013-03-06 2019-02-11 Incyte Holdings Corp PROCEDURES AND INTERMEDIATES FOR THE MANUFACTURE OF A JAK INHIBITOR
US9440971B2 (en) 2013-03-14 2016-09-13 Ratiopharm Gmbh Solid state forms of vemurafenib hydrochloride
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2014144850A1 (fr) 2013-03-15 2014-09-18 Genentech, Inc. Procédés de traitement d'un cancer et de prévention de la résistance médicamenteuse d'un cancer
PT2970265T (pt) 2013-03-15 2018-10-23 Plexxikon Inc Compostos heterocíclicos e suas utilizações
SG11201506688PA (en) 2013-03-15 2015-09-29 Sanofi Sa Anti-tumoral composition comprising a pi3kbeta inhibitor and a raf inhibitor, to overcome cancer cells resistance
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
TW201533028A (zh) 2013-05-30 2015-09-01 Plexxikon Inc 用於激酶調節之化合物及其適應症
CA2915250A1 (fr) 2013-06-13 2015-01-08 Biomatrica, Inc. Stabilisation de cellules
WO2014206344A1 (fr) 2013-06-28 2014-12-31 Beigene, Ltd. Composés amides tricycliques condensés comme inhibiteurs de kinases multiples
AR096892A1 (es) 2013-07-12 2016-02-03 Piramal Entpr Ltd Una combinación farmacéutica para el tratamiento del melanoma
WO2015017812A1 (fr) 2013-08-02 2015-02-05 Pharmacyclics, Inc. Méthodes permettant de traiter des tumeurs solides
SI3030227T1 (sl) 2013-08-07 2020-08-31 Incyte Corporation Dozirne oblike s podaljšanim sproščanjem za inhibitor JAK1
CA2920534A1 (fr) 2013-08-12 2015-02-19 Pharmacyclics Llc Methodes de traitement d'un cancer amplifie par her2
MX2016002367A (es) 2013-08-23 2016-10-28 Incyte Corp Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim.
WO2015041534A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk en combinaison avec raf/erk/mek
EP3046557A1 (fr) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Association de rock et de la voie mapk
CN105764896A (zh) 2013-09-30 2016-07-13 药品循环有限责任公司 布鲁顿氏酪氨酸激酶的抑制剂
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
WO2015058140A1 (fr) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Inhibiteurs polycycliques de kinase cycline-dépendante 7 (cdk7)
KR102338461B1 (ko) 2013-11-13 2021-12-13 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제 억제제의 제조 방법
PL3068776T3 (pl) 2013-11-13 2019-10-31 Vertex Pharma Inhibitory replikacji wirusów grypy
WO2015073864A1 (fr) 2013-11-15 2015-05-21 The Wisar Institute Of Anatomy And Biology Inhibiteurs d'ebna1 et leur procédé d'utilisation
WO2015075749A1 (fr) * 2013-11-22 2015-05-28 Laurus Labs Private Limited Nouveaux procédés de préparation de vemurafenib
CZ2013943A3 (cs) 2013-11-27 2015-06-03 Zentiva, K.S. Krystalické formy vemurafenibu
CN104710417B (zh) * 2013-12-11 2020-09-08 上海科州药物研发有限公司 氮杂吲哚类衍生物及其合成方法
CA3240745A1 (fr) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Traitement du cancer faisant appel a des associations d'inhibiteurs de l'erk et de la raf
CN104739823A (zh) * 2013-12-28 2015-07-01 复旦大学附属华山医院 淫羊藿素在制备维罗非尼增敏剂中的用途
WO2015108907A2 (fr) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions et méthodes pour l'identification, l'évaluation, la prévention, et le traitement d'un mélanome à l'aide d'isoformes de pd-l1
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2015164614A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase et leurs utilisations
WO2015164604A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
JP2017514866A (ja) * 2014-05-06 2017-06-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｂｒａｆ阻害剤を使用する創傷治癒
WO2015178770A1 (fr) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions pour le traitement du cancer
WO2015181628A1 (fr) * 2014-05-27 2015-12-03 Eisai R&D Management Co., Ltd. Traitement de la leucémie myéloïde aiguë avec un inhibiteur de hck
WO2015184305A1 (fr) 2014-05-30 2015-12-03 Incyte Corporation Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
EP3942931A1 (fr) 2014-06-10 2022-01-26 Biomatrica, INC. Stabilisation de thrombocytes à des températures ambiantes
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
EP3154588A1 (fr) * 2014-06-13 2017-04-19 Genentech, Inc. Méthodes de traitement et de prévention de la résistance médicamenteuse du cancer
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2016000615A1 (fr) * 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Composés hétéroaryles et leurs applications pharmaceutiques
TW201613919A (en) 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (fr) 2014-07-14 2016-01-21 Incyte Corporation Composés carboxamide hétéroaromatiques bicycliques utiles en tant qu'inhibiteurs de kinases pim
CN106573060A (zh) 2014-07-15 2017-04-19 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
WO2016019233A1 (fr) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
AU2015300798A1 (en) 2014-08-07 2017-02-02 Pharmacyclics Llc Novel formulations of a Bruton's tyrosine kinase inhibitor
LT3524595T (lt) 2014-08-28 2022-09-26 Eisai R&D Management Co., Ltd. Aukšto grynumo chinolino darinys ir jo gamybos būdas
AU2015318233B2 (en) 2014-09-15 2020-03-12 Plexxikon Inc. Heterocyclic compounds and uses thereof
US10040781B2 (en) 2014-09-26 2018-08-07 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
US10611765B2 (en) 2014-11-06 2020-04-07 Ohio State Innovation Foundation Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors
US10414764B2 (en) 2014-11-29 2019-09-17 Shilpa Medicare Limited Substantially pure vemurafenib and its salts
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016105518A1 (fr) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
WO2016140717A1 (fr) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CZ2015250A3 (cs) 2015-04-14 2016-10-26 Zentiva, K.S. Amorfní formy vemurafenibu
EP3292122B1 (fr) 2015-05-06 2020-01-15 Plexxikon Inc. Synthèse de dérivés 1h-pyrrolo[2,3-b]pyridine qui modulent les kinases
HRP20201383T1 (hr) 2015-05-06 2020-11-27 Plexxikon Inc. Kruti oblici spoja za moduliranje kinaza
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
EP3294717B1 (fr) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Procédés de préparation d'inhibiteurs de réplication des virus de la grippe
BR112017024481B1 (pt) 2015-05-14 2020-11-17 The Wistar Institute Of Anatomy And Biology composto inibidor de ebna1, composição farmacêutica compreendendo dito composto e usos terapêuticos do mesmo
CA2986739C (fr) 2015-05-22 2023-03-14 Plexxikon Inc. Plx -8394 ou plx-7904 a utiliser dans le traitement de maladies liees a braf v600
EP3298013A1 (fr) 2015-05-22 2018-03-28 Plexxikon Inc. Formes solides d'un composé de modulation des kinases
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
HRP20200064T1 (hr) * 2015-06-09 2020-04-03 Abbvie Inc. Modulatori nuklearnih receptora (ror) namijenjeni liječenju upalnih i autoimunih bolesti
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
WO2017011776A1 (fr) 2015-07-16 2017-01-19 Array Biopharma, Inc. Composés substitués de pyrazolo[1,5-a]pyridines comme inhibiteurs de la kinase ret
MY186368A (en) * 2015-07-20 2021-07-16 Genzyme Corp Colony stimulating factor-1 receptor (csf-1r) inhibitors
WO2017019804A2 (fr) 2015-07-28 2017-02-02 Plexxikon Inc. Composés et procédés de modulation des kinases, et indications associées
WO2017019664A1 (fr) 2015-07-28 2017-02-02 University Of Iowa Research Foundation Compositions et méthodes de traitement du cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
CA2996978A1 (fr) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dependantes
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
JP6863970B2 (ja) 2015-09-21 2021-04-21 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ヘテロ環式化合物およびそれらの使用
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017066193A1 (fr) 2015-10-15 2017-04-20 Princeton Drug Discovery, Llc Nouveaux inhibiteurs de protéines kinases
EP3368039A1 (fr) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Mutations ponctuelles dans le cancer résistant aux inhibiteurs de trk et méthodes associées
EP3377107B1 (fr) 2015-11-19 2020-08-12 H. Hoffnabb-La Roche Ag Méthodes de traitement du cancer au moyen d'inhibiteurs de b-raf et d'inhibiteurs de point de contrôle immunitaires
KR20180086247A (ko) 2015-12-07 2018-07-30 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법과 이들에 대한 징후
ES3037826T3 (en) 2015-12-08 2025-10-07 Biomatrica Inc Reduction of erythrocyte sedimentation rate
RU2018120366A (ru) 2015-12-14 2020-01-16 Рэд.Ком, Ллс Модульные цифровая камера и сотовый телефон
BR112017002594A2 (pt) 2015-12-17 2017-12-19 Gilead Sciences Inc compostos inibidores de cinase de ligação de tank
CN109195957A (zh) * 2016-02-25 2019-01-11 塔克西斯医药股份有限公司 合成方法和中间体
ES2904615T3 (es) 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
LT3439663T (lt) 2016-04-04 2024-10-10 Loxo Oncology, Inc. Vaikų vėžio gydymo būdai
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HUE068971T2 (hu) 2016-04-04 2025-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei
EP3443114A1 (fr) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Procédés diagnostiques et thérapeutiques relatifs au cancer
PT3800189T (pt) 2016-05-18 2023-07-27 Array Biopharma Inc Preparação de (s)-n-(5-((r)-2-(2,5- difluoropenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroxipirrolidina-1-carboxamida
EP3468548B1 (fr) * 2016-06-13 2021-08-04 ChemoCentryx, Inc. Méthodes de traitement du cancer du pancréas
EP3474879A4 (fr) 2016-06-24 2020-05-06 University of Iowa Research Foundation Compositions et procédés de traitement d'un mélanome
PL3478684T3 (pl) 2016-07-01 2020-08-10 Fermion Oy Nowe sposoby otrzymywania wemurafenibu
CN116478131A (zh) 2016-07-12 2023-07-25 锐新医药公司 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪
US10669278B2 (en) 2016-09-16 2020-06-02 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) TRAF 6 inhibitors
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
EP3308773A1 (fr) 2016-10-11 2018-04-18 Recordati Industria Chimica E Farmaceutica SPA Formulations de cystéamine et de dérivés de cystéamine
EP3528798A4 (fr) 2016-10-19 2020-10-21 United States Government as Represented by The Department of Veterans Affairs Compositions et méthodes pour le traitement du cancer
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
ES3015086T3 (en) 2016-11-23 2025-04-29 Chemocentryx Inc Ccr2 inhibitors for use in treating renal diseases
MX2018015452A (es) 2016-12-15 2020-02-10 Soc Des Produits Nestle S A Star Composiciones y metodos que modulan fosforo o las enzimas en un aminal de compañia.
US10723717B2 (en) * 2016-12-23 2020-07-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
WO2018136202A2 (fr) * 2016-12-23 2018-07-26 Plexxikon Inc. Composés et procédés pour la modulation de cdk8, et indications associées
ES2928773T3 (es) * 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
WO2018136663A1 (fr) 2017-01-18 2018-07-26 Array Biopharma, Inc. Inhibiteurs de ret
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
EP4230623A3 (fr) 2017-01-23 2023-10-11 Revolution Medicines, Inc. Composés de pyridine en tant qu'inhibiteurs allostériques de shp2
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2018175324A1 (fr) 2017-03-20 2018-09-27 The Broad Institute, Inc. Composés et méthodes de régulation de sécrétion d'insuline
US10577366B2 (en) 2017-03-20 2020-03-03 Plexxikon Inc. Crystalline forms of a compound that inhibits bromodomain
US11285154B2 (en) 2017-03-29 2022-03-29 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating cancer
US10774093B2 (en) 2017-03-30 2020-09-15 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates
EP3615083A4 (fr) * 2017-04-28 2021-05-19 Zamboni Chem Solutions Inc. Composés conjugués de dégradation de raf
WO2018210661A1 (fr) * 2017-05-15 2018-11-22 Basf Se Composés hétéroaryle faisant office de fongicides agrochimiques
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
KR102659322B1 (ko) 2017-05-19 2024-04-22 엔플렉션 테라퓨틱스, 인코포레이티드 피부병 치료를 위한 융합된 헤테로방향족-아닐린 화합물
CN111065393B (zh) * 2017-05-19 2023-08-18 恩福莱克逊治疗有限公司 用于治疗皮肤疾病的吡咯并吡啶-苯胺类化合物
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
PH12019502776A1 (en) 2017-06-30 2020-10-26 Univ California Compositions and methods for modulating hair growth
CN110944670B (zh) 2017-07-25 2023-03-10 普莱希科公司 调制激酶的化合物的制剂
CN109384785B (zh) * 2017-08-10 2021-09-28 浙江海正药业股份有限公司 吡咯并吡啶酮类衍生物、其制备方法及其在医药上的用途
MX2020002553A (es) 2017-09-08 2020-07-22 Hoffmann La Roche Metodos de diagnostico y terapeuticos para el cancer.
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3694504A4 (fr) 2017-10-11 2021-07-14 ChemoCentryx, Inc. Traitement de la glomérulosclérose segmentaire focale avec des antagonistes du ccr2
EP3694848A1 (fr) 2017-10-12 2020-08-19 Revolution Medicines, Inc. Pyridine, pyrazine et composés de triazine utilisés en tant qu'inhibiteurs allostériques de shp2
CA3079029A1 (fr) 2017-10-13 2019-04-18 Plexxikon Inc. Formes solides d'un compose pour la modulation de kinases
ES2947411T3 (es) 2017-10-26 2023-08-08 Xynomic Pharmaceuticals Inc Sales cristalinas de un campo inhibidor de quinasa B-RAF
EP3700574B1 (fr) 2017-10-27 2024-08-28 Plexxikon Inc. Formulation d'un composé modulant les kinases
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
AU2018385713A1 (en) 2017-12-15 2020-06-18 Revolution Medicines, Inc. Polycyclic compounds as allosteric SHP2 inhibitors
JP7416716B2 (ja) 2017-12-28 2024-01-17 トラクト ファーマシューティカルズ インコーポレイテッド 円柱上皮幹細胞のための幹細胞培養系およびそれに関連した使用法
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087972C (fr) 2018-01-18 2023-01-10 Array Biopharma Inc. Composes de pyrazolyl[4,3-c]pyridine substitues utilises en tant qu'inhibiteurs de la kinase ret
EP3740490A1 (fr) 2018-01-18 2020-11-25 Array Biopharma, Inc. Composés de pyrazolo[3,4-d]pyrimidine substitués utilisés en tant qu'inhibiteurs de la kinase ret
LT3746429T (lt) 2018-01-30 2022-05-10 Incyte Corporation (1-(3-fluor-2-(trifluormetil)izonikotinil)piperidin-4-ono) gamybos būdai
ES3000465T3 (en) 2018-01-31 2025-02-28 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3752200A1 (fr) 2018-02-13 2020-12-23 Vib Vzw Ciblage d'une maladie résiduelle minimale dans le cancer avec des antagonistes de rxr
US11149011B2 (en) 2018-03-20 2021-10-19 Plexxikon Inc. Compounds and methods for IDO and TDO modulation, and indications therefor
MY206999A (en) 2018-03-30 2025-01-23 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
WO2019195682A1 (fr) * 2018-04-05 2019-10-10 Beth Israel Deaconess Medical Center, Inc. Modulateurs du récepteur d'hydrocarbure aryle et utilisations associées
EP3560516A1 (fr) * 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Thérapie de combinaison comprenant du bêta-sitostérol en combinaison avec au moins un inhibiteur braf, un inhibiteur mek ou un inhibiteur erk et ses procédés et son utilisation
CN112543634A (zh) 2018-05-17 2021-03-23 威斯达研究所 Ebna1抑制剂晶体形式及其制备和使用方法
GB201808321D0 (en) * 2018-05-21 2018-07-11 Univ College Dublin Nat Univ Ireland Dublin Compositions and uses thereof
RU2687107C1 (ru) * 2018-06-18 2019-05-07 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид
US11731968B2 (en) 2018-06-21 2023-08-22 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
CA3105747A1 (fr) * 2018-07-06 2020-01-09 The Regents Of The University Of Colorado, A Body Corporate Systeme genetiquement code pour la construction et la detection d'agents biologiquement actifs
JP7365393B2 (ja) * 2018-07-16 2023-10-19 ヘパリジェニックス ゲーエムベーハー 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼ阻害剤
JP7317938B2 (ja) * 2018-07-19 2023-07-31 シェンチェン リンファン バイオテック カンパニー，リミティド アザインドール誘導体とＦＧＦＲ及びＣ－Ｍｅｔ阻害剤としてのその使用
WO2020028258A1 (fr) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Dispersions et formulations séchées par pulvérisation de (s)-5-amino-3-(4-((5-fluoro-2-méthoxybenzamido) méthyle)phényle)-1-(1,1,1-trifluoropropane-2-yl)-1 h-pyrazole-4-carboxamide
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
DK3860598T3 (da) 2018-10-03 2023-10-16 Jyvaeskylaen Yliopisto Vemurafenib og salte heraf til anvendelse til behandling af enterovirusinfektioner
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
JP2022504905A (ja) 2018-10-16 2022-01-13 ノバルティス アーゲー 標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷
AU2019381808A1 (en) * 2018-11-16 2021-05-27 1200 Pharma Llc ERK inhibitors and uses thereof
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
WO2020106306A1 (fr) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Composés cyanoaryl-aniline pour le traitement d'affections de la peau
CN113498340A (zh) 2018-11-20 2021-10-12 恩福莱克逊治疗有限公司 用于治疗皮肤疾病噻吩基苯胺化合物
US20220096454A1 (en) * 2018-12-03 2022-03-31 Merck Patent Gmbh Carboxylic acid derivatives
US12180207B2 (en) 2018-12-19 2024-12-31 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
EP3898615A1 (fr) 2018-12-19 2021-10-27 Array Biopharma, Inc. Dérivés de 7-((3,5-diméthoxyphényl)amino)quinoxaline servant d'inhibiteurs de fgfr pour le traitement du cancer
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
ES3015269T3 (en) * 2019-02-11 2025-04-30 Merck Patent Gmbh Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
BR112021019957A2 (pt) 2019-04-09 2021-12-07 Plexxikon Inc Azinas condensadas para modulação de ep300 ou cbp e indicações da mesma
WO2020223469A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
MA56047A (fr) * 2019-05-29 2022-04-06 Ifm Due Inc Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
AU2020283597A1 (en) * 2019-05-31 2021-11-25 Fochon Biosciences, Ltd. Substituted pyrrolo (2, 3-b) pyridine and pyrazolo (3, 4-b) pyridine derivatives as protein kinase inhibitors
AU2020320001B2 (en) 2019-07-29 2025-08-21 Heparegenix Gmbh Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
US20220347182A1 (en) * 2019-10-02 2022-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the treatment of osteoarthritis
BR112022006977A2 (pt) 2019-10-11 2022-09-20 Incyte Corp Aminas bicíclicas como inibidores de cdk2
CN111004210A (zh) * 2019-10-23 2020-04-14 中山大学 化合物单晶及其制备方法
US12509444B2 (en) 2019-12-06 2025-12-30 Plexxikon Inc. Compounds and methods for CD73 modulation and indications therefor
EP4069369A4 (fr) 2019-12-06 2024-02-14 Schrödinger, Inc. Composés cycliques et leurs procédés d'utilisation
CA3165168A1 (fr) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Composes et methodes pour la degradation ciblee du recepteur des androgenes
US20240018157A1 (en) 2019-12-27 2024-01-18 Schrödinger, Inc. Cyclic compounds and methods of using same
CA3164037A1 (fr) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Conjugues inhibiteurs d'alk5 et leurs utilisations
JP7639008B2 (ja) * 2020-01-15 2025-03-04 ヘパリジェニックス ゲーエムベーハー 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼ阻害剤
WO2021145729A1 (fr) * 2020-01-17 2021-07-22 Daegu-Gyeongbuk Medical Innovation Foundation Nouveau composé, son procédé de préparation et son utilisation
WO2021152005A1 (fr) 2020-01-28 2021-08-05 Universite De Strasbourg Oligonucléotide antisens ciblant linc00518 pour le traitement du mélanome
EP4135700A4 (fr) * 2020-04-15 2024-04-17 Pyramid Biosciences, Inc. Procédés de préparation d'inhibiteurs de récepteurs à activité tyrosine kinase
TW202206422A (zh) 2020-04-23 2022-02-16 美商普雷辛肯公司 用於ｃｄ７３調節之化合物及方法及其適應症
US11739088B2 (en) 2020-04-29 2023-08-29 Plexxikon Inc. Synthesis of heterocyclic compounds
KR102841083B1 (ko) * 2020-05-04 2025-07-31 아주대학교산학협력단 톨-유사 수용체 7/9 억제 기능이 있는 길항성 소분자 화합물
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
CA3192047A1 (fr) 2020-08-21 2022-02-24 Plexxikon Inc. Therapies anticancereuses a base de medicaments combinatoires
WO2022047145A1 (fr) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Composés de dégradation de protéine de fibrosarcome rapidement accéléré et leurs procédés d'utilisation
JP2023541047A (ja) 2020-09-10 2023-09-27 シュレーディンガー， インコーポレイテッド がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
US20240360154A1 (en) * 2020-09-23 2024-10-31 Genfleet Therapeutics (Shanghai) Inc. Aroyl substituted tricyclic compound, preparation method therefor and use thereof
CN114478528A (zh) * 2020-10-28 2022-05-13 劲方医药科技(上海)有限公司 芳甲酰取代的三环化合物及其制法和用途
CA3198254A1 (fr) * 2020-11-17 2022-05-27 Haohan TAN Derives de pyrrolo[2,3-b]pyridine et de pyrazolo[3,4-b]pyridine substitues en tant qu'inhibiteurs de proteine kinase
US20240002377A1 (en) * 2020-12-07 2024-01-04 Medshine Discovery Inc. Pyrrolopyridine compound and application thereof
WO2022125524A1 (fr) * 2020-12-07 2022-06-16 Lieber Institute, Inc. Composés d'inhibition de l'inositol hexakisphosphate kinase (ip6k) et leurs méthodes d'utilisation
EP4267573A1 (fr) 2020-12-23 2023-11-01 Genzyme Corporation Inhibiteurs deutérés du récepteur du facteur 1 de stimulation des colonies (csp-1r)
EP4284804A1 (fr) 2021-01-26 2023-12-06 Schrödinger, Inc. Composés tricycliques utiles dans le traitement du cancer, des troubles auto-immuns et des troubles inflammatoires
CN112574200B (zh) * 2021-02-26 2021-06-11 安润医药科技（苏州）有限公司 Btk和/或btk的突变体c481s的小分子抑制剂
CN115073469B (zh) * 2021-03-15 2023-12-22 药雅科技(上海)有限公司 吡咯并嘧啶类化合物作为激酶抑制剂的制备及其应用
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
TW202300150A (zh) 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
TW202304890A (zh) * 2021-04-14 2023-02-01 美商百歐克斯製藥公司 Klk5雙環雜芳香族抑制劑
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
KR102635126B1 (ko) 2021-05-27 2024-02-13 한국과학기술연구원 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 피롤로피리미딘 유도체 및 이들의 용도
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US20250042895A1 (en) * 2021-10-06 2025-02-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of ulk1 and methods of use
KR20240125577A (ko) 2021-11-23 2024-08-19 엔플렉션 테라퓨틱스, 인코포레이티드 피롤로피리딘-아닐린 화합물의 제형
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023174300A1 (fr) * 2022-03-15 2023-09-21 劲方医药科技(上海)有限公司 Forme cristalline d'un inhibiteur de btk, son sel acide de celui-ci, et forme cristalline du sel acide de celui-ci
US20250186439A1 (en) * 2022-03-16 2025-06-12 The Children's Medical Center Corporation Pyk2 inhibition modulates immune cell function
WO2023191425A1 (fr) * 2022-03-28 2023-10-05 주식회사 비엔에이치리서치 Méthode de criblage électrophysiologique pour médicaments
WO2024003350A1 (fr) 2022-06-30 2024-01-04 Universite De Strasbourg Polythérapie pour mélanome
CN115141197B (zh) * 2022-07-27 2024-03-26 安徽医科大学 一种3-芳杂环取代苯基衍生物及其制备方法与用途
WO2024033381A1 (fr) 2022-08-10 2024-02-15 Vib Vzw Inhibition de tcf4/itf2 dans le traitement du cancer
WO2024054591A1 (fr) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Composés de dégradation de fibrosarcome rapidement accéléré (raf) et procédés d'utilisation associés
CN120322558A (zh) * 2022-11-25 2025-07-15 吉诺利私人有限公司 核酸适配体
CN116768886B (zh) * 2022-12-26 2025-09-16 安徽医科大学 N-(4-(1H-吡咯并[2,3-b]吡啶-5-基)苯基)酰胺衍生物及制备与用途
CN115991705B (zh) * 2022-12-26 2025-04-08 安徽医科大学 3-(1H吡咯并[2,3-b]吡啶-5-基)苯甲酰基衍生物及其制备与应用
WO2024209717A1 (fr) 2023-04-06 2024-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 Composition pharmaceutique pour le traitement de tumeurs
WO2024258967A1 (fr) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anticorps anti-cd5 et leurs utilisations
CN117105936B (zh) * 2023-08-24 2025-01-24 遵义医科大学 一种作为FLT3抑制剂的咪唑并[1,2－a]吡啶化合物及其制备方法和用途
WO2025059027A1 (fr) 2023-09-11 2025-03-20 Schrödinger, Inc. Dérivés de cyclopenta[e]pyrazolo[1,5-a]pyrimidine utilisés en tant qu'inhibiteurs de malt1
WO2025097025A1 (fr) * 2023-11-03 2025-05-08 Evommune, Inc. Composés inhibiteurs de la protéine kinase c (pkc) thêta
WO2025146444A1 (fr) 2024-01-03 2025-07-10 Bayer Aktiengesellschaft Darolutamide en combinaison avec des inhibiteurs de braf et de mek pour le traitement d'un mélanome
WO2026019990A1 (fr) 2024-07-18 2026-01-22 Genentech, Inc. Méthodes de traitement du cancer avec des anticorps bispécifiques anti-ccr8/anti-cd3

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3124610A (en) * 1964-03-10 Preparation of intermediates
US2234705A (en) * 1940-04-12 1941-03-11 Eastman Kodak Co Cellulose organic derivative composition containing esters of monoalkoxy benzoic acids
US2413258A (en) * 1942-07-07 1946-12-24 United Gas Improvement Co Polystyrene-type resins plasticized with high boiling fatty acid alkyl esters
US3067237A (en) * 1959-04-14 1962-12-04 Sterling Drug Inc Lower-alkyl mono-or bis-(alkanesulfonamido) benzoate esters
GB1141949A (en) 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
CH513136A (de) * 1966-10-21 1971-09-30 Minnesota Mining & Mfg Verfahren zur Herstellung N-substituierter, einen Perfluorkohlenstoffrest aufweisender Sulfonamide
DE2413258A1 (de) 1974-03-20 1975-10-02 Bayer Ag Alkoxycarbonylphenylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als herbizide
IL46853A0 (en) * 1974-03-20 1975-05-22 Bayer Ag Novel alkoxycarbonylphenylureas,their preparation and their use as herbicides
GB1573212A (en) 1976-04-15 1980-08-20 Technicon Instr Immunoassay for gentamicin
US4301159A (en) * 1980-06-20 1981-11-17 Shionogi & Co., Ltd. N-(Diethylaminoethyl)-2-alkoxy-benzamide derivatives
AU547405B2 (en) * 1981-07-08 1985-10-17 Sanofi Amidobenzamides
US4664504A (en) * 1983-01-20 1987-05-12 Tokyo Shibaura Denki Kabushiki Kaisha Image forming apparatus
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4626513A (en) 1983-11-10 1986-12-02 Massachusetts General Hospital Method and apparatus for ligand detection
DE19775042I2 (de) * 1983-11-14 2001-05-03 Dowelanco 1, 2, 4-Triazolo 1, 4-a pyrimidin-2-Sulfonamide und zubereitungen und Methode zur Bekaempfung unerwuenschter Pflanzen und die Nitrierung von Ammonium-Stickstoff im Boden
AU567140B2 (en) * 1984-01-06 1987-11-12 Shionogi & Co., Ltd. Sulphonamido-benzamide derivatives
EP0154734B1 (fr) 1984-03-15 1990-08-29 Immunex Corporation Essai pour la détection immédiate d'un ligand, trousse d'essai et sa préparation
IT1196133B (it) * 1984-06-06 1988-11-10 Ausonia Farma Srl Derivati furanici con attivita' antiulcera
US4714693A (en) 1986-04-03 1987-12-22 Uop Inc. Method of making a catalyst composition comprising uniform size metal components on carrier
US5688655A (en) * 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US6054270A (en) * 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5658775A (en) * 1988-05-17 1997-08-19 Sloan-Kettering Institute For Cancer Research Double copy retroviral vector
JP3082204B2 (ja) * 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5527681A (en) * 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5360822A (en) * 1990-02-07 1994-11-01 Nippon Shinyaku Co. Ltd. Sulfonanilide derivatives and medicine
WO1991018088A1 (fr) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Vecteurs eucaryotiques a base de virus adeno-associes (aav)
DE4022414A1 (de) * 1990-07-13 1992-01-16 Bayer Ag Substituierte pyrrolo-pyridine
US5124335A (en) 1991-01-30 1992-06-23 Merck & Co., Inc. Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists
JPH06509578A (ja) * 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5632957A (en) * 1993-11-01 1997-05-27 Nanogen Molecular biological diagnostic systems including electrodes
FR2687402B1 (fr) * 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JPH05236997A (ja) * 1992-02-28 1993-09-17 Hitachi Ltd ポリヌクレオチド捕捉用チップ
DE69420394T2 (de) * 1993-03-01 2000-04-13 Merck Sharp & Dohme Ltd., Hoddesdon Pyrrolopyridinderivate als dopaminrezeptor liganden
US5576319A (en) * 1993-03-01 1996-11-19 Merck, Sharp & Dohme Ltd. Pyrrolo-pyridine derivatives
SK106395A3 (en) * 1993-03-01 1995-12-06 Merck Sharp & Dohme Treating and treatment or prevention of mental diseases
US5549614A (en) * 1993-03-18 1996-08-27 Tunis; Scott W. Apparatus for folding flexible intraocular lenses
US5840485A (en) * 1993-05-27 1998-11-24 Selectide Corporation Topologically segregated, encoded solid phase libraries
CA2163637C (fr) * 1993-05-27 2008-05-06 Michal Lebl Bibliotheques codees en phase solide, separees par topologie
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5426039A (en) * 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
JP3545461B2 (ja) 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
US6045996A (en) * 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US5965452A (en) * 1996-07-09 1999-10-12 Nanogen, Inc. Multiplexed active biologic array
US6468742B2 (en) * 1993-11-01 2002-10-22 Nanogen, Inc. Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5807522A (en) * 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5763198A (en) * 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
GB9416162D0 (en) 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
GB9416189D0 (en) 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
DE4430212A1 (de) * 1994-08-28 1996-02-29 Merck Patent Gmbh Ortho-substituierte Benzoesäure-Derivate
US5556752A (en) * 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5830645A (en) * 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
GB9503400D0 (en) 1995-02-21 1995-04-12 Merck Sharp & Dohme Therpeutic agents
GB2298199A (en) * 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
US5959098A (en) * 1996-04-17 1999-09-28 Affymetrix, Inc. Substrate preparation process
US6117681A (en) * 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
GB9507291D0 (en) * 1995-04-07 1995-05-31 Merck Sharp & Dohme Therapeutic agents
GB2299581A (en) 1995-04-07 1996-10-09 Merck Sharp & Dohme 3-(Tetrahydropyridin-1-yl-methyl)pyrrolo[2,3-b]pyridine derivatives as ligands for dopamine receptor subtypes
US6110456A (en) * 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US5856174A (en) * 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5866411A (en) * 1995-09-08 1999-02-02 Pedersen; Finn Skou Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector
US5747276A (en) * 1995-09-15 1998-05-05 The Scripps Research Institute Screening methods for the identification of novel antibiotics
US5721118A (en) * 1995-10-31 1998-02-24 The Regents Of The University Of California, San Diego Mammalian artificial chromosomes and methods of using same
US6022963A (en) * 1995-12-15 2000-02-08 Affymetrix, Inc. Synthesis of oligonucleotide arrays using photocleavable protecting groups
US6013440A (en) * 1996-03-11 2000-01-11 Affymetrix, Inc. Nucleic acid affinity columns
US6025155A (en) * 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
KR20000057137A (ko) * 1996-11-19 2000-09-15 스티븐 엠. 오드레 아릴 및 헤테로아릴로 치환된 융합 피롤 항염증제
US6294330B1 (en) * 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
CA2283434A1 (fr) * 1997-03-07 1998-09-11 Tropix, Inc. Essai d'inhibiteur de protease
US5977131A (en) 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
US6096718A (en) * 1997-06-05 2000-08-01 Gene Targeting Corp. Tissue specific adenovirus vectors for breast cancer treatment
BR9810456A (pt) 1997-06-27 2001-09-25 Fujisawa Pharmaceutical Co Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico
US6235769B1 (en) * 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6826296B2 (en) * 1997-07-25 2004-11-30 Affymetrix, Inc. Method and system for providing a probe array chip design database
US6161776A (en) * 1997-08-12 2000-12-19 Nibco Inc. Multi-layered, porous mat turf irrigation apparatus and method
JP2001515735A (ja) * 1997-09-11 2001-09-25 ジェノベイションズ， インコーポレイテッド 高密度アレイを作製する方法
US6178384B1 (en) * 1997-09-29 2001-01-23 The Trustees Of Columbia University In The City Of New York Method and apparatus for selecting a molecule based on conformational free energy
US6465178B2 (en) * 1997-09-30 2002-10-15 Surmodics, Inc. Target molecule attachment to surfaces
US6048695A (en) * 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
AU4543899A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6113913A (en) * 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
IL141724A0 (en) 1998-08-28 2002-03-10 Scios Inc INHIBITORS OF P38-α KINASE
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6277628B1 (en) * 1998-10-02 2001-08-21 Incyte Genomics, Inc. Linear microarrays
US6277489B1 (en) * 1998-12-04 2001-08-21 The Regents Of The University Of California Support for high performance affinity chromatography and other uses
US20010001449A1 (en) 1998-12-30 2001-05-24 Thomas R. Kiliany Low-pressure hydrocracking process
JP4619545B2 (ja) * 1999-03-17 2011-01-26 アストラゼネカ アクチボラグ アミド誘導体
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
US6221653B1 (en) * 1999-04-27 2001-04-24 Agilent Technologies, Inc. Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids
FR2793793B1 (fr) 1999-05-19 2004-02-27 Adir Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI234557B (en) * 1999-05-26 2005-06-21 Telik Inc Novel naphthalene ureas as glucose uptake enhancers
US6653151B2 (en) * 1999-07-30 2003-11-25 Large Scale Proteomics Corporation Dry deposition of materials for microarrays using matrix displacement
US20010008765A1 (en) * 1999-12-06 2001-07-19 Fuji Photo Film Co., Ltd. DNA chip and reactive solid carrier
EP1255536B1 (fr) * 1999-12-22 2006-06-28 Sugen, Inc. DERIVES D'INDOLINONE DESTINES A LA MODULATION DE LA TYROSINE PROTEINE KINASE DE TYPE c-KIT
AU776933B2 (en) 1999-12-28 2004-09-23 Eisai R&D Management Co., Ltd. Heterocyclic compounds having sulfonamide groups
JP2001278886A (ja) * 2000-03-28 2001-10-10 Dai Ichi Seiyaku Co Ltd ベンゾオキサジン誘導体及びこれを含有する医薬
GB0007934D0 (en) * 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
ES2280502T3 (es) 2001-02-21 2007-09-16 EISAI R&D MANAGEMENT CO., LTD. Metodo para evaluar el efecto de un inhibidor de la angiogenesis a traves de la inhibicion de la expresion de integrinas.
US7109208B2 (en) 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
WO2002085896A1 (fr) 2001-04-24 2002-10-31 Wyeth Derives azaheterocyclylmethyle antidepresseurs de 2,3-dihydro-1,4-benzodioxane
GB0114417D0 (en) * 2001-06-13 2001-08-08 Boc Group Plc Lubricating systems for regenerative vacuum pumps
WO2002102783A1 (fr) 2001-06-19 2002-12-27 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
US7291639B2 (en) 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
UA75425C2 (en) 2001-07-09 2006-04-17 Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
US6858860B2 (en) * 2001-07-24 2005-02-22 Seiko Epson Corporation Apparatus and method for measuring natural period of liquid
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
WO2003028724A1 (fr) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Inhibiteurs de la kinase chk1
JPWO2003037862A1 (ja) 2001-10-30 2005-02-17 日本新薬株式会社 アミド誘導体及び医薬
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
US6884889B2 (en) 2002-03-25 2005-04-26 Bristol-Myers Squibb Co. Processes for the preparation of antiviral 7-azaindole derivatives
ATE457312T1 (de) 2002-03-28 2010-02-15 Eisai R&D Man Co Ltd Azaindole als hemmstoffe von c-jun n-terminalen kinasen
IL164187A0 (en) 2002-03-28 2005-12-18 Eisai Co Ltd 7-Azaindole derivatives and pharmaceutical compositions containing the same
GB0212785D0 (en) * 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US6878887B2 (en) * 2002-08-07 2005-04-12 Matsushita Electric Industrial Co., Ltd. Anti-malfunction mechanism for variable output device
SE0202463D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
PT2277551E (pt) 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
WO2004024895A2 (fr) 2002-09-16 2004-03-25 Plexxikon, Inc. Structure cristalline de la proteine kinase pim-1
CN1744899A (zh) * 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 作为ccr5拮抗剂的哌啶衍生物
ATE405269T1 (de) * 2002-12-13 2008-09-15 Smithkline Beecham Corp Cyclohexylverbindungen als ccr5-antagonisten
US7696225B2 (en) * 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
CN100482662C (zh) * 2003-02-14 2009-04-29 惠氏公司 作为5-羟基色胺-6配体的杂环基-3-磺酰基氮杂吲哚或-氮杂吲唑衍生物
JP2007524374A (ja) * 2003-02-28 2007-08-30 プレキシコン，インコーポレーテッド Ｐｙｋ２結晶構造および使用
WO2005028624A2 (fr) 2003-09-15 2005-03-31 Plexxikon, Inc. Echafaudages moleculaires pour le developpement de ligands des proteines kinases
DE10357510A1 (de) 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
SI1696920T1 (sl) * 2003-12-19 2015-02-27 Plexxikon Inc. Spojine in postopki za razvoj modulatorjev ret
DK2119771T3 (en) 2003-12-24 2018-12-10 Dupont Nutrition Biosci Aps PROTEINS
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0403635D0 (en) 2004-02-18 2004-03-24 Devgen Nv Pyridinocarboxamides with improved activity as kinase inhibitors
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
KR101216372B1 (ko) 2004-03-30 2013-01-04 버텍스 파마슈티칼스 인코포레이티드 Ｊａｋ 및 기타 단백질 키나제의 억제제로서 유용한 아자인돌
AU2005265017A1 (en) * 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
US7498342B2 (en) * 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
CA2572058A1 (fr) 2004-06-30 2006-01-12 Vertex Pharmaceuticals Incorporated Azaindoles utilises comme inhibiteurs de proteine kinases
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CA2573573A1 (fr) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Modulateurs heterocycliques a cycles fusionnes pour les kinases
EP1781654A1 (fr) * 2004-07-27 2007-05-09 SGX Pharmaceuticals, Inc. Modulateurs de kinases à base de pyrrolopyridine
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
GB0419192D0 (en) * 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
US8859581B2 (en) 2005-04-25 2014-10-14 Merck Patent Gmbh Azaheterocyclic compounds as kinase inhibitors
WO2007013896A2 (fr) * 2005-05-17 2007-02-01 Plexxikon, Inc. Composes modulant l'activite de c-kit et c-fms et utilisations
US8921376B2 (en) 2005-05-20 2014-12-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
WO2007109604A2 (fr) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques
WO2008063888A2 (fr) * 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
WO2008079909A1 (fr) * 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
CL2008001540A1 (es) * 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor

Also Published As

Publication number Publication date
NO333913B1 (no) 2013-10-21
TW200804370A (en) 2008-01-16
TWI522337B (zh) 2016-02-21
TW201345906A (zh) 2013-11-16
US20160176865A1 (en) 2016-06-23
LU92035I9 (fr) 2019-01-04
PL1893612T3 (pl) 2012-01-31
BE2012C028I2 (fr) 2026-01-14
CN102206216B (zh) 2014-11-12
US20120053177A1 (en) 2012-03-01
AR078519A2 (es) 2011-11-16
HK1164866A1 (en) 2012-09-28
EP2395004A3 (fr) 2012-04-04
UA95244C2 (ru) 2011-07-25
PL2395004T3 (pl) 2016-08-31
US20130261117A1 (en) 2013-10-03
CN102603581B (zh) 2015-06-24
NZ565255A (en) 2010-04-30
US8415469B2 (en) 2013-04-09
RU2565071C2 (ru) 2015-10-20
BRPI0611863B1 (pt) 2021-11-23
SI1893612T1 (sl) 2012-03-30
RU2629999C2 (ru) 2017-09-05
KR20080030619A (ko) 2008-04-04
EP1893612A1 (fr) 2008-03-05
US20100249118A1 (en) 2010-09-30
CY1111996T1 (el) 2015-08-05
RU2011101140A (ru) 2012-07-20
CN101243084B (zh) 2012-03-07
MY153898A (en) 2015-04-15
HUE027370T2 (en) 2016-10-28
AR054624A1 (es) 2007-07-04
CN102206216A (zh) 2011-10-05
DE122012000043I1 (de) 2012-09-13
BRPI0611863A2 (pt) 2008-12-02
WO2007002325A1 (fr) 2007-01-04
CR9677A (es) 2008-03-26
HUS1200009I1 (hu) 2018-09-28
RU2008100933A (ru) 2009-07-27
EP3088400A1 (fr) 2016-11-02
PE20070100A1 (es) 2007-03-10
NO2014006I2 (no) 2014-03-20
WO2007002433A1 (fr) 2007-01-04
CR20130216A (es) 2013-07-02
US20180111929A1 (en) 2018-04-26
ECSP088121A (es) 2008-02-20
JP5007304B2 (ja) 2012-08-22
ATE518860T1 (de) 2011-08-15
JP2008546797A (ja) 2008-12-25
AU2006261993A1 (en) 2007-01-04
RU2418800C2 (ru) 2011-05-20
IL188248A (en) 2012-04-30
PT1893612E (pt) 2011-11-21
US7863288B2 (en) 2011-01-04
EP2395004B1 (fr) 2016-01-20
CA2613015A1 (fr) 2007-01-04
NO20076659L (no) 2008-03-18
CN101243084A (zh) 2008-08-13
KR101125919B1 (ko) 2012-06-12
ZA200711152B (en) 2012-06-27
US20100256365A1 (en) 2010-10-07
AU2006261993B2 (en) 2011-11-17
RU2012150759A (ru) 2014-06-10
HK1114610A1 (en) 2008-11-07
US20120022098A1 (en) 2012-01-26
CN102603581A (zh) 2012-07-25
CY2012021I1 (el) 2015-08-05
RS52010B (sr) 2012-04-30
TWI473808B (zh) 2015-02-21
ES2565992T3 (es) 2016-04-08
EP1893612B1 (fr) 2011-08-03
DK2395004T3 (en) 2016-03-21
SI2395004T1 (sl) 2016-05-31
US8143271B2 (en) 2012-03-27
EP2395004A2 (fr) 2011-12-14
TWI432193B (zh) 2014-04-01
US20110059963A1 (en) 2011-03-10
US20150290205A1 (en) 2015-10-15
CY2012021I2 (el) 2015-08-05
ZA201202024B (en) 2016-02-24
IL188248A0 (en) 2008-04-13
ZA201202025B (en) 2022-03-30
MX2007016463A (es) 2008-03-04
TW201514140A (zh) 2015-04-16
NO2014006I1 (no) 2014-06-02
ZA201202026B (en) 2012-11-28
LU92035I2 (fr) 2012-08-28
US8470818B2 (en) 2013-06-25
MY147410A (en) 2012-11-30
DK1893612T3 (da) 2011-11-21
US20130303534A1 (en) 2013-11-14
CA2613015C (fr) 2012-04-03
ES2371397T3 (es) 2011-12-30

Similar Documents

Publication Publication Date Title
MA29612B1 (fr) Composes et methodes de modulation de la kinase et instructions afferentes
MA31153B1 (fr) Composés et méthodes pour moduler une kinase et indications associées
MA31704B1 (fr) Composés et compositions de 5-(4- (haloalkoxy) phényl) pyrimidine-2-amine utilisés comme inhibiteurs de kinases
MA30888B1 (fr) Compositions et procedes de modulation de recepteurs de c-kit et de facteur de croissance derive de plaquettes (pdgfr)
MA28679B1 (fr) Composes et compositions utilises comme inhibiteurs de proteines kinases
EP2111107A4 (fr) Agonistes de récepteur hétérocyclique pour le traitement du diabète et de troubles métaboliques
NO20091989L (no) Forbindelser som modulerer c-fms og/eller C-kit aktivitet og deres anvendelse
MA31167B1 (fr) Inhibiteurs de l'activite de akt
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
BRPI0415210A (pt) compostos e composições como inibidores de proteìna cinase
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA29216B1 (fr) Composes et compositions utilises comme inhibiteurs de la proteine kinase
MA30076B1 (fr) Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases.
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
TW200637547A (en) Compounds and compositions as protein kinase inhibitors
WO2003104410A3 (fr) Enzymes
MA31260B1 (fr) 3-imidazolyl-indoles pour le traitement de maladies proliferatives
EA201070012A1 (ru) МЕТАБОЛИТЫ (R)-3-(4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА, ИНГИБИТОРА JANUS КИНАЗ
MA30900B1 (fr) Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3
MA29141B1 (fr) Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases
TNSN07070A1 (fr) Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases
MA31918B1 (fr) Agents et épitopes de liaison à wise
WO2006002262A3 (fr) Genes et voies exprimes de maniere differentielle dans des troubles bipolaires et/ou troubles depressifs majeurs
DK1592786T3 (da) Diagnosticering og behandling af multipel sulfatase-defekt og andet ved anvendelse af et formylglycin-dannende enzym (FGE).
NO20082880L (no) Inhibitorer av C-MET samt anvendelse derav